oxybutynin has been researched along with Peripheral Nerve Diseases in 10 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in patients with peripheral neuropathic pain." | 9.15 | Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain. ( Lu, B; Murphy, FT; Peppin, JF; Tobias, JK; Vanhove, GF; Webster, LR, 2011) |
| "Neuropathic pain is defined as a direct consequence of an injury or disease that affects the somatosensory system, which may affect 7 to 10% of the world population." | 5.56 | Peripheral Neuropathy Associated with Hypereosinophilic Syndrome: A Clinical Therapeutic Success with Capsaicin 8% Patch. ( Gestosa, SVS; Lares, AMG; Mulenas, NME; Ruivo, EFM, 2020) |
| "To assess efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in patients with peripheral neuropathic pain." | 5.15 | Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain. ( Lu, B; Murphy, FT; Peppin, JF; Tobias, JK; Vanhove, GF; Webster, LR, 2011) |
| "Analgesic treatment of peripheral neuropathic pain with the capsaicin 8% cutaneous patch is safe and effective." | 2.78 | Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study. ( Heskamp, ML; Maihofner, C, 2013) |
| "Neuropathic pain is defined as a direct consequence of an injury or disease that affects the somatosensory system, which may affect 7 to 10% of the world population." | 1.56 | Peripheral Neuropathy Associated with Hypereosinophilic Syndrome: A Clinical Therapeutic Success with Capsaicin 8% Patch. ( Gestosa, SVS; Lares, AMG; Mulenas, NME; Ruivo, EFM, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ruivo, EFM | 1 |
| Gestosa, SVS | 1 |
| Mulenas, NME | 1 |
| Lares, AMG | 1 |
| Cabezón-Gutiérrez, L | 1 |
| Custodio-Cabello, S | 1 |
| Palka-Kotlowska, M | 1 |
| Khosravi-Shahi, P | 1 |
| Sibiya, N | 1 |
| Mabandla, M | 1 |
| Simpson, DM | 1 |
| Brown, S | 1 |
| Tobias, JK | 2 |
| Vanhove, GF | 2 |
| Maihofner, C | 1 |
| Heskamp, ML | 1 |
| Kochhar, JS | 1 |
| Lim, WX | 1 |
| Zou, S | 1 |
| Foo, WY | 1 |
| Pan, J | 1 |
| Kang, L | 1 |
| Giménez-Milà, M | 1 |
| Videla, S | 1 |
| Navarro, MA | 1 |
| Faulí, A | 1 |
| Ojeda, A | 1 |
| Bogdanovich, A | 1 |
| Moreno, LA | 1 |
| Hernández-Cera, C | 1 |
| Busquets, C | 1 |
| Misery, L | 1 |
| Erfan, N | 1 |
| Castela, E | 1 |
| Brenaut, E | 1 |
| Lantéri-Minet, M | 1 |
| Lacour, JP | 1 |
| Passeron, T | 1 |
| Burness, CB | 1 |
| McCormack, PL | 1 |
| Webster, LR | 1 |
| Peppin, JF | 1 |
| Murphy, FT | 1 |
| Lu, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Controlled Dose Finding Study of NGX-4010 for the Treatment of Painful HIV-Associated Distal Symmetrical Polyneuropathy[NCT00064623] | Phase 3 | 300 participants | Interventional | 2003-08-31 | Completed | ||
| Safety and Feasibility of High-Dose Topical Capsaicin for the Treatment of Neuropathic Pain in Pediatric Sickle Cell Disease[NCT03899246] | Phase 1 | 10 participants (Actual) | Interventional | 2019-07-03 | Completed | ||
| A Randomized, Open-Label Study of the Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain[NCT00082316] | Phase 2 | 0 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for oxybutynin and Peripheral Nerve Diseases
| Article | Year |
|---|---|
High-Dose 8% Capsaicin Patch in Treatment of Chemotherapy-Induced Peripheral Neuropathy. A Systematic Review.
Topics: Antineoplastic Agents; Capsaicin; Humans; Peripheral Nervous System Diseases; Prospective Studies; R | 2020 |
Capsaicin 8 % Patch: A Review in Peripheral Neuropathic Pain.
Topics: Capsaicin; Diabetic Neuropathies; Humans; Neuralgia, Postherpetic; Pain Management; Peripheral Nervo | 2016 |
3 trials available for oxybutynin and Peripheral Nerve Diseases
| Article | Year |
|---|---|
NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: results of a 52-week open-label study.
Topics: Adult; Capsaicin; Double-Blind Method; Endpoint Determination; Female; HIV Infections; Humans; Kapla | 2014 |
Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study.
Topics: Administration, Cutaneous; Analgesics; Capsaicin; Female; Humans; Male; Middle Aged; Neuralgia; Pain | 2013 |
Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain.
Topics: Aged; Anesthetics, Local; Capsaicin; Diabetic Neuropathies; Drug-Related Side Effects and Adverse Re | 2011 |
5 other studies available for oxybutynin and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Peripheral Neuropathy Associated with Hypereosinophilic Syndrome: A Clinical Therapeutic Success with Capsaicin 8% Patch.
Topics: Capsaicin; Humans; Hypereosinophilic Syndrome; Male; Middle Aged; Neuralgia; Pain Management; Periph | 2020 |
The pectin-insulin patch application prevents the onset of peripheral neuropathy-like symptoms in streptozotocin-induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Disease Models, Animal; Disease Progression; Hand Strength | 2018 |
Microneedle integrated transdermal patch for fast onset and sustained delivery of lidocaine.
Topics: Administration, Cutaneous; Adult; Animals; Female; Humans; Lidocaine; Male; Peripheral Nervous Syste | 2013 |
Assessment of the feasibility of high-concentration capsaicin patches in the pain unit of a tertiary hospital for a population of mixed refractory peripheral neuropathic pain syndromes in non-diabetic patients.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics; Capsaicin; Feasibility Studie | 2014 |
Successful treatment of refractory neuropathic pruritus with capsaicin 8% patch: a bicentric retrospective study with long-term follow-up.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antipruritics; Capsaicin; Female; France; Humans | 2015 |